GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2500-2505

  Kern, Delila J ^a   James, Britnie R ^a   Blackwell, Sue ^b   Gassner, Christian ^c   Klein, Christian ^d   Weiner, George J ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d Roche Glycart AG   (Switzerland)

Author keywords

Antibody based immunotherapy; Lymphoma; NK cell biology

Indexed keywords

COMPLEMENT COMPONENT C1Q; OBINUTUZUMAB; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BURKITT LYMPHOMA; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE; COMPLEMENT C1Q; COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PROTEIN BINDING;

EID: 84883264834     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.781169     Document Type: Article

References (29)

1. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase 1 multiple-dose trial in patients with relapsed non-Hodgkin?s lymphoma J Clin Oncol 1997 15 3266-3274.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
3. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008;8:759-768.
4. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-Cell lymphoproliferative disorders is mediated in vitro by a caspase-1ndependent mechanism involving the generation of reactive oxygen species. Blood 2001;98: 277 1-2777.
5. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 200 1;98:1352-1357.
6. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-1587.
7. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006;91:176-183.
8. Wang SY, Racila E, Taylor RP, et al. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008;111:1456-1463.
9. Wang SY,Veeramani 5, RacilaE, et al. Depletion ofthe C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009;114:5322-5330.
10. Cragg MS, Morgan SM, Chan HI, et al. Complement-mediated lysis by anti-CD2O mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-1052.
11. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD2O and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;1 19:2143-2159.
12. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD2O antibody therapy through the engineering of a new type 11 anti-CD2O antibody with enhanced direct-and immune effector cell-mediated B-Cell cytotoxicity. Blood 2010;115:4393-4402.
13. Robak EL GA-lOl, a third-generation, humanized and glycoengineered anti-CD2O niAb for the treatment of B-Cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10:588-596.
14. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type 11, glycoengineered, anti-CD2O monoclonal antibody GA1O1 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186: 3762-3769.
15. Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD2O antibodies rituximab and GA1O1 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152:295-306.
16. Dalle 5, Reslan L, Besseyre de Horts I, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD2O antibody GA1O1. Mol Cancer Ther 2011;10:178-185.
17. Weiner GJ. Rituximab: Mechanism of action. Semin Hematol 2010;47:115-123.
18. Golay J, Lazzari M, Facchinetti V, et al. CD2O levels determine the in vitro susceptibility to rituximab and complement of B-Cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 200 1;98:3383-3389.
19. Coiffier B, Lepretre 5, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD2O antibody, in patients with relapsed or refractory B-Cell chronic lymphocytic leukemia: A phase 1-2 study. Blood 2008;111:1094-1100.
20. Kennedy AD, Beum pg Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD2O loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-3288.
21. Beum pg Lindorfer MA, Taylor RR Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NEC cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916-2924.
22. Clynes R, Takechi Y, Moroi Y, et al. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95:652-656.
23. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD2O monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRllla gene. Blood 2002;99:754-758.
24. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaR11IA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom?s macroglobulinemia. J Clin Oncol 2005;23:474-481.
25. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-3947.
26. Bowles IA, Wang SY, Link BK, et al. Anti-CD2O monoclonal antibody with enhanced affinity for CD16 activates NEC cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-2654.
27. Beers SA, Chan CH, James 5, et al. Type 11 (tositumomab) antiCD2O monoclonal antibody outperforms type 1 (rituximab-like) reagents in B-Cell depletion regardless of complement activation. Blood 2008;112:4170-4177.
28. Pievani A, Belussi C, Klein C, et al. Enhanced killing of human B-Cell lymphoma targets by combined use of cytokine-Induced killer cell (CIK) cultures and anti-CD2O antibodies. Blood 2011;117: 510-518.
29. Rafiq 5, Butchar JP, Cheney C, et al. Comparative assessment of clinically utilized CD2O-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NEC cell, monocyte, and macrophage properties. J Immunol 2013; 190:2702-2711.